|
Vaxiion Therapeutics
San Diego, USA
|
|
Vaxiion Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company’s lead product, VAX014, is an oncolytic immunotherapy based on recombinant bacterial minicells (rBMCs) designed to selectively target and destroy cancer cells while stimulating an anti-tumor immune response.